Tabla S IX.
Analysis of the evolution of the LP of the different generic Everolimus medicines approved in Spain with respect to the innovative drug.
| Drug type & company | CIPM approval date | Marketing authorization date | CIPM LP (€/mg)* | Interval since 1st Gx approval by CIPM (years) | Price difference vs innovative price | Price difference vs 1st Gx approved by CIPM |
|---|---|---|---|---|---|---|
| Innovative (Novartis) | 08/07/2010 | 17/09/2009 | 16.89 | NA | NA | NA |
| Generic 1 (Stada) | 30/11/2018 | 01/07/2018 | 7.094 | 0 | -58% | NA |
| Generic 2 (Accord) | 28/02/2019 | 01/10/2018 | 7.094 | 0.2 | -58% | 0% |
| Generic 3 (Krka) | 28/02/2019 | 01/10/2018 | 7.094 | 0.2 | -58% | 0% |
| Generic 4 (Reddy Pharma) | 28/02/2019 | 01/09/2018 | 7.094 | 0.2 | -58% | 0% |
| Generic 5 (Sandoz) | 30/06/2019 | 01/03/2019 | 7.094 | 0.6 | -58% | 0% |
| Generic 6 (Tamarang) | 29/02/2020 | 01/05/2019 | 5.777 | 1.2 | -66% | -19% |
| Generic 7 (Mylan) | 31/05/2020 | 09/01/2020 | 5.777 | 1.5 | -66% | -19% |
| Generic 8 (Medicare) | 31/07/2020 | 19/09/2019 | 5.777 | 1.7 | -66% | -19% |
* In the case of the innovative medicine, the authorized LP at the time of marketing of the first generic drug is indicated.